INHIBIKASE
Live / Registered — Registered (as of 04 Jun 2024)
What this means for you
Registered since 04 Jun 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97625784
- Registration number
- 7409853
- Mark type
- Stylized text
- Filed
- 10 Oct 2022
- Published for opposition
- 17 Oct 2023
- Registered
- 04 Jun 2024
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neurodegenerative disease and cancer
- Class 042 — Scientific and technological services: Pharmaceutical research and development; medical and scientific research and development; scientific laboratory services; scientific and technological services, namely, pre-clinical and clinical scientific evaluation in the fields of neurodegenerative disease, cancer and biological research
Owner
- Inhibikase Therapeutics, Inc., Atlanta, GA, US
- Inhibikase Therapeutics, Inc., Atlanta, GA, US
- Inhibikase Therapeutics, Inc., Atlanta, GA, US
Prior registrations
Prosecution history
- 07 Apr 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 07 Apr 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 07 Apr 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 07 Apr 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 07 Apr 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 04 Jun 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 04 Jun 2024 — REGISTERED-PRINCIPAL REGISTER
- 29 Apr 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 29 Apr 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 22 Apr 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 02 Apr 2024 — USE AMENDMENT FILED
- 22 Apr 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 02 Apr 2024 — TEAS STATEMENT OF USE RECEIVED
- 12 Dec 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Oct 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED